Literature DB >> 25704436

Nivolumab for advanced squamous cell lung cancer: what are the next steps?

Ramon Andrade de Mello1, Inés Pousa2, Deolinda Pereira2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25704436     DOI: 10.1016/S1470-2045(15)70074-4

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  6 in total

1.  TG4010 immunotherapy: a novel weapon against advanced non-small cell lung cancer?

Authors:  Ramon Andrade de Mello
Journal:  Ann Transl Med       Date:  2016-05

Review 2.  Immunotherapy for lung cancer: for whom the bell tolls?

Authors:  Pedro Madureira; Ramon Andrade de Mello; Alessandro de Vasconcelos; Yan Zhang
Journal:  Tumour Biol       Date:  2015-03-04

Review 3.  Predictive factors of activity of anti-programmed death-1/programmed death ligand-1 drugs: immunohistochemistry analysis.

Authors:  Nitin Chakravarti; Victor G Prieto
Journal:  Transl Lung Cancer Res       Date:  2015-12

Review 4.  Potential role of immunotherapy in advanced non-small-cell lung cancer.

Authors:  Ramon Andrade de Mello; Ana Flávia Veloso; Paulo Esrom Catarina; Sara Nadine; Georgios Antoniou
Journal:  Onco Targets Ther       Date:  2016-12-16       Impact factor: 4.147

Review 5.  Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor.

Authors:  Liting Guo; Haijun Zhang; Baoan Chen
Journal:  J Cancer       Date:  2017-02-10       Impact factor: 4.207

6.  Significant benefit of Nivolumab treating PD-L1 positive metastatic pulmonary carcinosarcoma: a case report and literature review.

Authors:  Zhe Zhang; Yishan Chen; Mingxia Ma; Junli Hao; Rui Ding; Lixin Han; Jiayun Zou; Lina Zhang; Qin Meng; Xiujuan Qu; Yunpeng Liu; Mingfang Zhao
Journal:  Oncotarget       Date:  2017-07-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.